Mezzion Pharma

Mezzion Pharma is a South Korean drug-development company focused on creating new medicines for conditions such as single-ventricle heart disease, pulmonary arterial hypertension, erectile dysfunction, enlarged prostate, portal hypertension, and autosomal dominant polycystic kidney disease.

Its pipeline targets patients and healthcare systems globally, with the US Food and Drug Administration as a key regulatory gatekeeper. Listed on KOSDAQ, Korea's tech and small-cap board, the company's business centres entirely on clinical-stage drug development rather than commercialised product sales.